https://ansm.sante.fr/informations-de-securite/zolgensma-onasemnogene-abeparvovec-cas-dinsuffisance-hepatique-aigue-dissue-fatale 2023 false false false France French pharmacovigilance note risk onasemnogene abeparvovec-xioi Onasemnogene Abeparvovec onasemnogene abeparvovec liver function tests continuity of patient care Monitoring of liver function (regime/therapy) liver failure, acute child infant liver failure, acute guidelines for drug use
--- https://ansm.sante.fr/informations-de-securite/zolgensma-r-onasemnogene-abeparvovec-risque-de-microangiopathie-thrombotique 2021 false false false France French pharmacovigilance note Onasemnogene Abeparvovec onasemnogene abeparvovec thrombotic microangiopathies gene therapy spinal muscular atrophies of childhood infusions, intravenous guidelines for drug use drug monitoring continuity of patient care infant onasemnogene abeparvovec-xioi genetic therapy Zolgensma biological products recombinant fusion proteins
--- https://ansm.sante.fr/tableau-atu-rtu/zolgensma-2-x-1013-genomes-de-vecteur-ml-solution-pour-perfusion 2021 false true false France French Onasemnogene Abeparvovec Onasemnogene Abeparvovec summary of product characteristics package leaflet guidelines for drug use onasemnogene abeparvovec spinal muscular atrophies of childhood HMN (Hereditary motor neuropathy) proximal type I infusions, intravenous onasemnogene abeparvovec-xioi Zolgensma biological products recombinant fusion proteins